SuperworthaTYR PHARMA INC revenue ATYR
Sales by quarter and over the last twelve months, from 2019.
- Last 12 months, to Mar 31, 2026
- $190K
- Latest quarter, Q1 FY26
- $0
- Fiscal year 2025
- $190K
- −19% on the year before
aTYR PHARMA INC's revenue was $190K over the twelve months to Mar 31, 2026.
In its latest quarter, Q1 FY26, it was $0.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $190K | −19% |
| FY2024 | $235K | −33% |
| FY2023 | $353K | n/a |
| FY2022 | n/a | n/a |
| FY2020 | $10.5M | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY26 | $0 | n/a | $190K | |
| Q4 FY25 | $0 | n/a | $190K | |
| Q3 FY25 | $190K | n/a | $190K | |
| Q2 FY25 | $0 | n/a | $0 | |
| Q1 FY25 | $0 | −100% | $0 | |
| Q4 FY24 | $0 | n/a | $235K | |
| Q3 FY24 | $0 | −100% | $235K | |
| Q2 FY24 | $0 | n/a | $588K | |
| Q1 FY24 | $235K | n/a | $588K | |
| Q4 FY23 | $0 | −100% | $353K | |
| Q3 FY23 | $353K | n/a | $10.7M | |
| Q2 FY23 | $0 | n/a | $10.4M |
Against its peers
Companies in Healthcare nearest aTYR PHARMA INC's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| ATYRaTYR PHARMA INC | n/m | |
| NEPHNephros | $20.7M | +24% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| APTAlpha Pro Tech | $61.9M | +6% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| ICCCImmucell | $30.7M | +8% a year |
| KEQUKewaunee Scientific | $277.2M | +5% a year |
| Peer median | $54.5M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on aTYR PHARMA INC
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.